10x Genomics CEO Serge Saxonov Sells 10,486 Shares

What Happened
Serge Saxonov, CEO of 10x Genomics (TXG), sold a total of 10,486 shares in open-market transactions on August 26, 2026, raising approximately $667,900. The sales were reported as three disposals: 3,500 shares at a weighted average price of $63.02 ($220,580), 6,494 shares at $63.98 ($415,465), and 492 shares at $64.75 ($31,855). These were sales (not purchases), commonly viewed as routine disposals rather than a direct bullish signal.

Key Details

• Transaction date: August 26, 2026; Form 4 filed August 28, 2026 (appears timely).
• Total shares sold: 10,486; total proceeds: about $667,900.
• Tranche details (weighted average prices reported):
  • 3,500 shares @ $63.02 = $220,580 (multiple trades at $62.53–$63.50 per F2)
  • 6,494 shares @ $63.98 = $415,465 (multiple trades at $63.56–$64.54 per F3)
  • 492 shares @ $64.75 = $31,855 (multiple trades at $64.59–$64.99 per F4)
• Reporting code: S (Sale).
• Shares after transaction: not specified in the information you provided.
• Notable footnotes: sales were made under a Rule 10b5-1 trading plan adopted Nov 29, 2025 (F1). The seller serves as trustee for trusts that hold shares (Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust — F5–F7). Seller has offered to provide trade-by-trade breakdowns upon request (F2–F4).

Context
A 10b5-1 plan means these sales were pre-arranged automatic trades and are often scheduled for compliance/tax or diversification reasons; they do not necessarily reflect a change in the insider’s view of the company. For retail investors, purchases by insiders tend to be more informative about confidence; routine sales like this are common and may be for personal or estate/trust management reasons.